Hansen CR, Bertelsen AS, Hazell I, Stougaard SW, Johansen J, Overgaard J, et al. Eliminating the high-risk CTV1 margin in DAHANCA oropharyngeal radiotherapy: Dosimetric impact on dysphagia and organ-at-risk doses. AO [Internet]. 2025 Sep. 11 [cited 2026 May 26];64:1205-11. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/44049